{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T13:42:03Z","timestamp":1782222123127,"version":"3.54.5"},"reference-count":92,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.cpcardiol.2023.101660","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T13:27:29Z","timestamp":1677245249000},"page":"101660","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Identification of Potent Small-Molecule PCSK9 Inhibitors Based on Quantitative Structure-Activity Relationship, Pharmacophore Modeling, and Molecular Docking Procedure"],"prefix":"10.1016","volume":"48","author":[{"given":"Ali","family":"Mahmoudi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra E.","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6690-6874","authenticated-orcid":false,"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tannaz","family":"Jamialahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2023.101660_bib0001","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105499","article-title":"Optimal use of lipid-lowering therapy after acute coronary syndromes: a position paper endorsed by the International Lipid Expert Panel (ILEP)","volume":"166","author":"Banach","year":"2021","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0003","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0004","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.5114\/aoms\/141941","article-title":"PoLA\/CFPiP\/PCS\/PSLD\/PSD\/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021","volume":"17","author":"Banach","year":"2021","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0005","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S0140-6736(21)01122-3","article-title":"Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)","volume":"398","author":"Vallejo-Vaz","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0006","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.atherosclerosis.2019.06.899","article-title":"The prevalence and management of familial hypercholesterolemia in patients with acute coronary syndrome in the Polish tertiary centre: results from the TERCET registry with 19,781 individuals","volume":"288","author":"Dyrbu\u015b","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0007","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.atherosclerosis.2018.08.051","article-title":"Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)","volume":"277","author":"Collaboration","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jjcc.2017.07.002","article-title":"PCSK9 inhibition in the management of familial hypercholesterolemia","volume":"71","author":"Ogura","year":"2018","journal-title":"J Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0009","first-page":"569","article-title":"Which patients at risk of cardiovascular disease might benefit the most from inclisiran? Polish experts' opinion. The compromise between EBM and possibilities in healthcare","volume":"18","author":"Banach","year":"2022","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0010","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0011","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.phrs.2017.03.023","article-title":"Regulation of PCSK9 by nutraceuticals","volume":"120","author":"Momtazi","year":"2017","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0012","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s10557-013-6479-4","article-title":"New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect?","volume":"27","author":"Sahebkar","year":"2013","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0013","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.clinthera.2013.06.019","article-title":"New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes","volume":"35","author":"Sahebkar","year":"2013","journal-title":"Clin Ther"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0014","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.acvd.2013.10.007","article-title":"PCSK9: from discovery to therapeutic applications","volume":"107","author":"Farnier","year":"2014","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0015","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1194\/jlr.M018093","article-title":"Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors","volume":"52","author":"Holla","year":"2011","journal-title":"J Lipid Res"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0016","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1161\/01.ATV.0000134621.14315.43","article-title":"Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia","volume":"24","author":"Dubuc","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0017","doi-asserted-by":"crossref","first-page":"28856","DOI":"10.1074\/jbc.M109.037085","article-title":"Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route","volume":"284","author":"Poirier","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0018","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1172\/JCI29383","article-title":"Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice","volume":"116","author":"Lagace","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0019","doi-asserted-by":"crossref","first-page":"18602","DOI":"10.1074\/jbc.M702027200","article-title":"Binding of proprotein convertase subtilisin\/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation","volume":"282","author":"Zhang","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0020","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.143812","article-title":"microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production","volume":"5","author":"Dong","year":"2020","journal-title":"JCI insight"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0021","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0022","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11883-014-0439-8","article-title":"Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs","volume":"16","author":"Abifadel","year":"2014","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0023","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng1509","article-title":"Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9","volume":"37","author":"Cohen","year":"2005","journal-title":"Nat Genet"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0024","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0025","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ejmech.2018.11.011","article-title":"Small molecules as inhibitors of PCSK9: current status and future challenges","volume":"162","author":"Xu","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2021.106057","article-title":"Efficacy and safety of PCSK9 inhibitors in stroke prevention","volume":"30","author":"Moustafa","year":"2021","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0027","first-page":"966","article-title":"QSAR Study of 17\u03b2-HSD3 inhibitors by genetic algorithm-support vector machine as a target receptor for the treatment of prostate cancer","volume":"16","author":"Pourbasheer","year":"2017","journal-title":"Iran J Pharm Res"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0028","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/j.drudis.2018.05.041","article-title":"Bioinformatics-based tools in drug discovery: the cartography from single gene to integrative biological networks","volume":"23","author":"Ramharack","year":"2018","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0029","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1021\/ci900498n","article-title":"HPPD: ligand- and target-based virtual screening on a herbicide target","volume":"50","author":"L\u00f3pez-Ramos","year":"2010","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0030","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1359-6446(02)02483-2","article-title":"Structure-based virtual screening: an overview","volume":"7","author":"Lyne","year":"2002","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0031","doi-asserted-by":"crossref","first-page":"7210","DOI":"10.1021\/acs.jmedchem.1c00416","article-title":"Target-based evaluation of \"Drug-Like\" properties and ligand efficiencies","volume":"64","author":"Leeson","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0032","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/bioinformatics\/btz665","article-title":"Learning from the ligand: using ligand-based features to improve binding affinity prediction","volume":"36","author":"Boyles","year":"2020","journal-title":"Bioinformatics"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115344","article-title":"A small molecule inhibitor of PCSK9 that antagonizes LDL receptor binding via interaction with a cryptic PCSK9 binding groove","volume":"28","author":"Evison","year":"2020","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0034","unstructured":"Wu C, Yan J, Xu W, et al. Piperidine compounds as PCSK9 inhibitors. In: Google Patents; 2019."},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0035","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.bmcl.2018.02.046","article-title":"Small molecule modulators of PCSK9 - a literature and patent overview","volume":"28","author":"Pettersen","year":"2018","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0036","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1016\/j.bmcl.2019.06.014","article-title":"Discovery of 2,3\u2032-diindolylmethanes as a novel class of PCSK9 modulators","volume":"29","author":"Winston-McPherson","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0037","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ejmech.2018.11.011","article-title":"Small molecules as inhibitors of PCSK9: Current status and future challenges","volume":"162","author":"Xu","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0038","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1021\/acsmedchemlett.0c00388","article-title":"Novel cyclic tetramer compounds as PCSK9 inhibitors for treating metabolic disorders","volume":"11","author":"Sabnis","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0039","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1074\/jbc.M113.514067","article-title":"Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor","volume":"289","author":"Zhang","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0040","doi-asserted-by":"crossref","unstructured":"Sun H, Wang J, Liu S, Zhou X, Dai L. Discovery of novel small molecule inhibitors disrupting the PCSK9-LDLR interaction. 2021;61:5269-5279. https:\/\/doi.org\/10.1021\/acs.jcim.1c00521.","DOI":"10.1021\/acs.jcim.1c00521"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0041","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1758-2946-3-33","article-title":"Open babel: an open chemical toolbox","volume":"3","author":"O'Boyle","year":"2011","journal-title":"J Cheminform"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0042","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.drudis.2016.06.013","article-title":"Descriptors and their selection methods in QSAR analysis: paradigm for drug design","volume":"21","author":"Danishuddin","year":"2016","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0043","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/jcc.21707","article-title":"PaDEL-descriptor: an open source software to calculate molecular descriptors and fingerprints","volume":"32","author":"Yap","year":"2011","journal-title":"J Computat Chem"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0044","doi-asserted-by":"crossref","first-page":"10312","DOI":"10.1038\/srep10312","article-title":"Application of high-dimensional feature selection: evaluation for genomic prediction in man","volume":"5","author":"Bermingham","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0045","series-title":"Understanding the Basics of QSAR for Applications in Pharmaceutical Sciences and Risk Assessment","first-page":"p231","article-title":"Chapter 7 - validation of QSAR Models","author":"Roy","year":"2015"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0046","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.chemolab.2015.07.007","article-title":"NanoBRIDGES\u201d software: Open access tools to perform QSAR and nano-QSAR modeling","volume":"147","author":"Ambure","year":"2015","journal-title":"Chemometr Intellig Laborat Syst"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0047","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1590\/S0103-50532012005000073","article-title":"Chemoface: a novel free user-friendly interface for chemometrics","volume":"23","author":"Nunes","year":"2012","journal-title":"J Braz Chem Soc"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0048","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.aca.2014.12.056","article-title":"Sum of ranking differences (SRD) to ensemble multivariate calibration model merits for tuning parameter selection and comparing calibration methods","volume":"869","author":"Kalivas","year":"2015","journal-title":"Analytica Chimica Acta"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0049","doi-asserted-by":"crossref","first-page":"5872","DOI":"10.1364\/AO.57.005872","article-title":"Partial least squares regression calculation for quantitative analysis of metals submerged in water measured using laser-induced breakdown spectroscopy","volume":"57","author":"Takahashi","year":"2018","journal-title":"Appl Opt"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0050","series-title":"LigPrep, version 3. 5","author":"Schr\u00f6dinger","year":"2015"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0051","series-title":"4: Maestro","author":"Release","year":"2017"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0052","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1747-0285.2006.00384.x","article-title":"PHASE: a novel approach to pharmacophore modeling and 3D database searching","volume":"67","author":"Dixon","year":"2006","journal-title":"Chem Biol Drug Design"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0053","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1021\/acs.jcim.5b00559","article-title":"ZINC 15 \u2013 ligand discovery for everyone","volume":"55","author":"Sterling","year":"2015","journal-title":"J Chem Informat Model"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0054","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ijpharm.2018.07.046","article-title":"Drug metabolites and their effects on the development of adverse reactions: revisiting Lipinski's Rule of Five","volume":"549","author":"Chagas","year":"2018","journal-title":"Int J Pharm"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0055","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s10822-006-9087-6","article-title":"PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results","volume":"20","author":"Dixon","year":"2006","journal-title":"J Comput Aided Mol Des"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0056","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/978-1-4939-7000-1_26","article-title":"Protein Data Bank (PDB): the single global macromolecular structure archive","volume":"1607","author":"Burley","year":"2017","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0057","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nsmb1235","article-title":"Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia","volume":"14","author":"Cunningham","year":"2007","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0058","doi-asserted-by":"crossref","first-page":"13045","DOI":"10.1073\/pnas.0806312105","article-title":"Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor","volume":"105","author":"Zhang","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0059","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1194\/jlr.M011445","article-title":"A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo","volume":"52","author":"Ni","year":"2011","journal-title":"J Lipid Res"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0060","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/978-1-4939-2269-7_19","article-title":"Small-molecule library screening by docking with PyRx","volume":"1263","author":"Dallakyan","year":"2015","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0061","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera\u2013a visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J Comput Chem"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0062","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/5273914","article-title":"Molecular mechanism of the effect of huanglian jiedu decoction on type 2 diabetes mellitus based on network pharmacology and molecular docking","volume":"2020","author":"Yin","year":"2020","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0063","unstructured":"Biovia DS. Discovery studio visualizer. San Diego, CA, USA 2017;936."},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0064","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3390\/biom9100556","article-title":"Pharmacophore directed screening of agonistic natural molecules showing affinity to 5HT(2C) receptor","volume":"9","author":"Veeramachaneni","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0065","doi-asserted-by":"crossref","unstructured":"Fan N, Zhang S, Sheng T, et al.\u00a0Docking field-based QSAR and pharmacophore studies on the substituted pyrimidine derivatives targeting HIV-1 reverse transcriptase. 2018;91:398-407. https:\/\/doi.org\/10.1111\/cbdd.13086.","DOI":"10.1111\/cbdd.13086"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0066","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.bcp.2013.09.007","article-title":"Pharmacokinetics","volume":"87","author":"Fan","year":"2014","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0067","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1107\/S0021889892009944","article-title":"PROCHECK: a program to check the stereochemical quality of protein structures","volume":"26","author":"Laskowski","year":"1993","journal-title":"J Appl Crystallograp"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0068","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S0076-6879(97)77022-8","article-title":"Verify3D: assessment of protein models with three-dimensional profiles","volume":"277","author":"Eisenberg","year":"1997","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0069","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/pro.5560020916","article-title":"Verification of protein structures: patterns of nonbonded atomic interactions","volume":"2","author":"Colovos","year":"1993","journal-title":"Protein Sci"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0070","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.3390\/molecules25071726","article-title":"Theoretical studies aimed at finding FLT3 inhibitors and a promising compound and molecular pattern with dual aurora B\/FLT3 activity","volume":"25","author":"Fernandes","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0071","first-page":"183","article-title":"QSAR and docking studies on xanthone derivatives for anticancer activity targeting DNA topoisomerase II\u03b1","volume":"8","author":"Alam","year":"2014","journal-title":"Drug Design, Devel Ther"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0072","doi-asserted-by":"crossref","first-page":"7407","DOI":"10.1111\/jcmm.16769","article-title":"Axl-inhibitor bemcentinib alleviates mitochondrial dysfunction in the unilateral ureter obstruction murine model","volume":"25","author":"Hoel","year":"2021","journal-title":"J Cell Mole Med"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0073","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/1759-7714.14259","article-title":"Low baseline plasma PCSK9 level is associated with good clinical outcomes of immune checkpoint inhibitors in advanced non-small cell lung cancer","volume":"13","author":"Xie","year":"2022","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0074","first-page":"645","article-title":"Rec INN","volume":"43","author":"Bemcentinib","year":"2018","journal-title":"Drugs Future"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0075","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1182\/blood-2016-09-736892","article-title":"Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma","volume":"129","author":"Gayle","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0076","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1002\/art.34339","article-title":"Brief report: a phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12\/interleukin-23 inhibitor, in patients with rheumatoid arthritis","volume":"64","author":"Krausz","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0077","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/01.ibd.0000225337.14356.31","article-title":"A phase 1\/2A trial of STA 5326, an oral interleukin-12\/23 inhibitor, in patients with active moderate to severe Crohn's disease","volume":"12","author":"Burakoff","year":"2006","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0078","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/ibd.21159","article-title":"Randomized, double-blind, placebo-controlled trial of the oral interleukin-12\/23 inhibitor apilimod mesylate for treatment of active Crohn's disease","volume":"16","author":"Sands","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0079","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1182\/blood-2006-04-019398","article-title":"Selective abrogation of Th1 response by STA-5326, a potent IL-12\/IL-23 inhibitor","volume":"109","author":"Wada","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0080","doi-asserted-by":"crossref","first-page":"e35069","DOI":"10.1371\/journal.pone.0035069","article-title":"Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis","volume":"7","author":"Wada","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0081","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1002\/art.34339","article-title":"A phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12\/interleukin-23 inhibitor, in patients with rheumatoid arthritis","volume":"64","author":"Krausz","year":"2012","journal-title":"Arthrit Rheumat"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0082","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1021\/acsmedchemlett.6b00122","article-title":"Discovery of MK-7145, an oral small molecule ROMK inhibitor for the treatment of hypertension and heart failure","volume":"7","author":"Tang","year":"2016","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0083","doi-asserted-by":"crossref","first-page":"24261","DOI":"10.1016\/S0021-9258(19)51076-6","article-title":"Cloning and characterization of multiple forms of the human kidney ROM-K potassium channel","volume":"269","author":"Shuck","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0084","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1517\/13543784.2011.565329","article-title":"Brivanib alaninate for cancer","volume":"20","author":"Diaz-Padilla","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0085","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/bjc.2011.182","article-title":"Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy","volume":"105","author":"Garrett","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0086","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s00280-011-1603-2","article-title":"Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumors","volume":"68","author":"LoRusso","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0087","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.jaad.2013.03.021","article-title":"A phase II, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis","volume":"69","author":"Sigurgeirsson","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0088","first-page":"23","article-title":"A Phase 1, randomized, open-label crossover study to evaluate the safety and pharmacokinetics of 400 mg albaconazole administered to healthy participants as a tablet formulation versus a capsule formulation","volume":"5","author":"van Rossem","year":"2013","journal-title":"Clin Pharmacol"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0089","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.jaad.2013.03.021","article-title":"A phase II, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis","volume":"69","author":"Sigurgeirsson","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0090","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.atherosclerosis.2011.10.029","article-title":"Effects of the PPAR-\u03b4 agonist MBX-8025 on atherogenic dyslipidemia","volume":"220","author":"Choi","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0091","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.5114\/aoms\/133885","article-title":"PCSK9 immunization using nanoliposomes: preventive efficacy against hypercholesterolemia and atherosclerosis","volume":"17","author":"Momtazi-Borojeni","year":"2021","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.cpcardiol.2023.101660_bib0092","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1210\/jc.2011-1061","article-title":"MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin","volume":"96","author":"Bays","year":"2011","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280623000774?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280623000774?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T11:05:15Z","timestamp":1729076715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280623000774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":92,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0146280623000774"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.101660","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of Potent Small-Molecule PCSK9 Inhibitors Based on Quantitative Structure-Activity Relationship, Pharmacophore Modeling, and Molecular Docking Procedure","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.101660","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"101660"}}